Myeloid-derived suppressor cells: a novel therapeutic target.
about
Nano-gold corking and enzymatic uncorking of carbon nanotube cupsDendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccinationThe biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity.Analysis of prognostic factors in lymphoma patients with bone marrow involvement: a single center cohort study.Down-regulation of S100A9 inhibits osteosarcoma cell growth through inactivating MAPK and NF-κB signaling pathways.The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOPMyeloid derived suppressor cells: Targets for therapy.Review of S100A9 biology and its role in cancer.Update on vaccine development for renal cell cancer.Myeloid-derived suppressor cells: natural regulators for transplant tolerance.Deficiency of Kruppel-like factor KLF4 in mammary tumor cells inhibits tumor growth and pulmonary metastasis and is accompanied by compromised recruitment of myeloid-derived suppressor cellsA Th1 cytokine-enriched microenvironment enhances tumor killing by activated T cells armed with bispecific antibodies and inhibits the development of myeloid-derived suppressor cellsCancer-associated myeloproliferation: old association, new therapeutic target.Myeloid-derived suppressor cells--their role in haemato-oncological malignancies and other cancers and possible implications for therapy.Mechanisms of action of tasquinimod on the tumour microenvironment.Cellular and molecular mechanisms in cancer immune escape: a comprehensive review.Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.The role of individual inheritance in tumor progression and metastasis.Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes.On the origin of myeloid-derived suppressor cells.One microenvironment does not fit all: heterogeneity beyond cancer cells.Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent mannerOrigin and pharmacological modulation of tumor-associated regulatory dendritic cells.Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer.The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma.Detection of inflammatory cell function using (13)C magnetic resonance spectroscopy of hyperpolarized [6-(13)C]-arginine.Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer.Arginase inhibition suppresses lung metastasis in the 4T1 breast cancer model independently of the immunomodulatory and anti-metastatic effects of VEGFR-2 blockade.The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma.
P2860
Q23924065-BD118187-F9CC-47AE-8D36-04EF5B56BAA2Q34759603-559A96FF-B92C-4CB5-A610-15CC6705E92BQ35750663-0A79197E-FAE3-4585-93F8-77D1900C1BF9Q35959252-5E56741D-3334-4D6D-9A71-CB2E4BCCF0B7Q35971858-B374995A-AA7E-4783-B40B-155FFD6527AAQ36216519-7EAC6375-F378-4AB4-BBFE-E3C3DEE35E3AQ36845851-3E7897B6-B3AF-4667-8F13-9EFB0365F53EQ36896567-FDD0E139-6B12-48A3-92D6-0BF0BCE43A1AQ36989720-AA7FDB1D-36C1-4A76-9898-5C467C6CD8D9Q37019136-F5567C90-3E9A-4518-AD2A-1EBD860EA16EQ37228480-5BE54665-3768-4E54-B353-E6DDFBA40BB2Q37238430-514EE694-6343-4D65-BA0F-3766BF3CC829Q37769017-71FD885D-E038-411C-BE0B-6C6CF55675A2Q37863217-33B6C233-1C8C-4158-87F4-5F39B07ED354Q38155757-98806950-79A1-49B1-8183-3D50EE15D5ACQ38170150-80226F02-9045-44A1-A9F4-61F49AB0569CQ38514440-585A138D-1CC4-4522-A3F9-E3552F0D4E0FQ38521016-73D8E395-E0B5-4892-AAA9-6EDC42963A5AQ38920881-3FB06488-5A98-41A5-9321-3197F8784F1FQ38968944-DFDBF1D1-866E-4715-9B98-FAF1CC04BD70Q39011826-0244B1BD-ED23-4131-9D8A-4F50379E5758Q39405279-6688C47A-5E12-4B58-916F-9EA7D5DE990AQ39858290-65B4CCC0-62F0-4722-A81E-05C088CC6952Q42183073-60D30540-E64C-424E-9EDC-670D0A4B3A91Q42317563-9C2A4211-907E-4365-813D-EB0C444E74C2Q42368949-008C4251-1333-486F-80FC-4739CA341800Q47350013-941F27FF-E0B7-45F0-BDC4-071B29428F0AQ52763518-84347892-4844-427E-A884-68E7B74EB946Q53153100-45537B06-5D2E-4FE9-8B70-E41226BF0B2A
P2860
Myeloid-derived suppressor cells: a novel therapeutic target.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Myeloid-derived suppressor cells: a novel therapeutic target.
@en
Myeloid-derived suppressor cells: a novel therapeutic target.
@nl
type
label
Myeloid-derived suppressor cells: a novel therapeutic target.
@en
Myeloid-derived suppressor cells: a novel therapeutic target.
@nl
prefLabel
Myeloid-derived suppressor cells: a novel therapeutic target.
@en
Myeloid-derived suppressor cells: a novel therapeutic target.
@nl
P2093
P2860
P1476
Myeloid-derived suppressor cells: a novel therapeutic target.
@en
P2093
James H Fincke
Jennifer S Ko
Ronald M Bukowski
P2860
P2888
P356
10.1007/S11912-009-0014-6
P577
2009-03-01T00:00:00Z